Centerline biomedical: FDA Cleared Endovascular Therapy 3D Navigation Technology
Centerline biomedical: FDA Cleared Endovascular Therapy 3D Navigation Technology
Centerline biomedical: FDA Cleared Endovascular Therapy 3D Navigation Technology
Project highlight: The world's first commercialized 3D navigation/GPS company for intraoperative management, providing physicians with a safe, real-time imaging solution that significantly improves clinical outcomes, lowers costs and reduces radiation time for patients and caregivers during surgery.
Investment stage: Series B round
Project
Project highlight: The world's first commercialized 3D navigation/GPS company for intraoperative management, providing physicians with a safe, real-time imaging solution that significantly improves clinical outcomes, lowers costs and reduces radiation time for patients and caregivers during surgery.
Investment stage: Series B round
Project update: Completed B round financing of $25M, led by Cleveland clinic fund. The company's product has been used in many well-known hospitals such as Cleveland clinics, Allegheny general, university of Maryland medical center, university Virginia, etc.
CarslMed: Individualized treatment plan for adult spinal deformity
Centerline biomedical: FDA Cleared Endovascular Therapy 3D Navigation Technology
Centerline biomedical: FDA Cleared Endovascular Therapy 3D Navigation Technology
Project highlight: The world's first company that uses artificial intelligence and 3D printing technology to provide customized treatment plans for adult spinal deformities
Investment stage: Seed round joint lead investment, continue to participate in Series A round
Project update: October 2021, the company received the New Technology Add-o
Project highlight: The world's first company that uses artificial intelligence and 3D printing technology to provide customized treatment plans for adult spinal deformities
Investment stage: Seed round joint lead investment, continue to participate in Series A round
Project update: October 2021, the company received the New Technology Add-on Payment (NTAP) from CMS for aprevo®. CMS provides an additional maximum payment of $40,950 for aprevo®, when used in the inpatient hospital setting for fiscal year 2022. This add-on payment will be incremental to the below MS-DRG payment for qualifying Medicare inpatient cases.
Leo Cancer Care: Upright radiotherapy solution
Centerline biomedical: FDA Cleared Endovascular Therapy 3D Navigation Technology
Smartlens: Convenient and affordable treatment for Glaucoma
Project highlight: The world's first supplier of upright radiotherapy equipment with lower cost and fewer side effects on patients
Investment stage: Series B round
Project update: July 2021, Leo Cancer Care raised $25.3m in Series B funding. Investors included Pureland Global Venture, Yu Galaxy, WARF, Alumni Ventures, Junson Capital and Ser
Project highlight: The world's first supplier of upright radiotherapy equipment with lower cost and fewer side effects on patients
Investment stage: Series B round
Project update: July 2021, Leo Cancer Care raised $25.3m in Series B funding. Investors included Pureland Global Venture, Yu Galaxy, WARF, Alumni Ventures, Junson Capital and Serra Ventures as well as industry leaders CHC, Cosylab, Toret Devices and Radiation Business Solutions.
Smartlens: Convenient and affordable treatment for Glaucoma
Smartlens: Convenient and affordable treatment for Glaucoma
Smartlens: Convenient and affordable treatment for Glaucoma
Project highlight: The first device capable of monitoring IOP as a non-invasive, easy to use, electronics-free, and low-cost solution giving doctors a better tool for Glaucoma management.
Investment stage: Pre-A round
Project update: Recently, Smartlens raised $3M for its Pre-A funding. Investors included Sophia Pharmaceuticals and Fund of Glaucoma Associates of Texas.
Deepvoxel: AI-driven medical imaging diagnosis technology
Smartlens: Convenient and affordable treatment for Glaucoma
Deepvoxel: AI-driven medical imaging diagnosis technology
Project highlight: The only software product in this field that provides customers with customized organ-at-risk (OAR) automatic delineation based on AI technology.
Investment stage: Pre-A round
Project update: The company has established commercial cooperation with five hospitals, including City of Hope and Hoag Hospital. It is planned to
Project highlight: The only software product in this field that provides customers with customized organ-at-risk (OAR) automatic delineation based on AI technology.
Investment stage: Pre-A round
Project update: The company has established commercial cooperation with five hospitals, including City of Hope and Hoag Hospital. It is planned to cooperate with more than 10 hospitals by the end of 2021.
iDENTICAL: 3D dental implant
Smartlens: Convenient and affordable treatment for Glaucoma
Deepvoxel: AI-driven medical imaging diagnosis technology
Project highlight: iDENTICAL shortens the patient's implantation and healing time through personalized, drill-free dental implants, and completely changes the experience of tooth replacement.
Investment stage: Seed round
Project update: Kicked-off the $15M Series A fundraising process in September 2021. Proceeds from the Series A will be us
Project highlight: iDENTICAL shortens the patient's implantation and healing time through personalized, drill-free dental implants, and completely changes the experience of tooth replacement.
Investment stage: Seed round
Project update: Kicked-off the $15M Series A fundraising process in September 2021. Proceeds from the Series A will be used to support the pilot and pivotal clinical studies and 510(k) clearance.
Perceptive Medical: Blood pressure management system
Telesair: Respiratory care equipment for lung diseases
Telesair: Respiratory care equipment for lung diseases
Project highlight: Using the world's first breakthrough technology to solve the problem of inefficient blood pressure management in the intensive care unit (ICU) and operating room.
Investment stage: Seed round
Project update: Completed seed round of financing and raised $1.15M for equipment design and prototype design.
Telesair: Respiratory care equipment for lung diseases
Telesair: Respiratory care equipment for lung diseases
Telesair: Respiratory care equipment for lung diseases
Project highlight: Developed the market-leading next-generation respiratory care equipment that is safer and more efficient for use in clinics and homes
Investment stage: Seed round
Project update: Completed Seed round financing and cooperated with two major investment platforms, NewChips and Launchpad. The company is planning for the next round of financing.
This website uses cookies.
We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.